Plain-English translation of NCT05188118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to treat advanced kidney cancer using two proven medications — and a combination of plus — given in a specific sequence rather than all at once. Researchers believe this approach may work just as well as giving the medications together, but with fewer serious side effects.
Right now, doctors aren't sure which order or combination of approved kidney cancer medications works best for patients. Some combinations are very effective but cause tough side effects, while others are gentler but don't work for everyone. This trial is trying to find a middle ground by testing whether giving the medication in a planned sequence reduces side effects while still fighting the cancer effectively.
You likely qualify if…
You likely don't qualify if…
You will start by taking (a pill) for 12 weeks. After that, you'll receive the combination of and (given by IV infusion) over the next 12 weeks. Depending on how your cancer responds, you may continue with additional medication for another 12 weeks. Throughout the trial, you'll have regular blood tests, scans, and doctor visits to monitor your health and how the treatment is working.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States